CJC-1295 and Ipamorelin Dosing
There are no FDA-approved dosing guidelines for CJC-1295 (non-DAC) combined with ipamorelin in healthy adults, and no major medical society has issued recommendations for their use. These peptides remain investigational and are not approved for therapeutic use outside of research settings.
Evidence from Clinical Research
CJC-1295 (non-DAC) Dosing from Human Studies
In healthy adults aged 21-61 years, single subcutaneous doses of CJC-1295 ranging from 30-60 mcg/kg were well tolerated and produced sustained increases in growth hormone and IGF-I levels 1.
The 60 mcg/kg dose resulted in a 2- to 10-fold increase in mean plasma GH concentrations lasting 6 days or more, and a 1.5- to 3-fold increase in IGF-I levels persisting 9-11 days 1.
The estimated half-life of CJC-1295 was 5.8-8.1 days, allowing for infrequent dosing 1.
Weekly or biweekly dosing maintained elevated IGF-I levels above baseline for up to 28 days after multiple doses 1.
A single injection of 60-90 mcg/kg increased basal GH levels 7.5-fold while preserving normal pulsatile GH secretion patterns 2.
Ipamorelin Dosing from Human Studies
In healthy male volunteers, ipamorelin was administered via 15-minute infusions at doses ranging from 4.21 to 140.45 nmol/kg 3.
The pharmacokinetic profile showed a short terminal half-life of 2 hours, clearance of 0.078 L/h/kg, and volume of distribution of 0.22 L/kg 3.
Ipamorelin induced a single episode of GH release with peak levels at approximately 40 minutes across all dose levels 3.
The concentration required for half-maximal GH stimulation (SC50) was 214 nmol/L, with a maximal GH production rate of 694 mIU/L/h 3.
Critical Safety Considerations
Lack of Regulatory Approval
Neither CJC-1295 nor ipamorelin is FDA-approved for any indication in humans.
These compounds are classified as research chemicals and their use outside of approved clinical trials carries significant medicolegal and safety risks.
Monitoring Requirements from Research Protocols
Research protocols measured GH and IGF-I levels at baseline and throughout treatment to assess response 1, 2.
Renal function, hepatic function, and metabolic parameters were monitored in clinical studies 1.
Adverse events were systematically tracked, though no serious adverse reactions were reported in the published trials at doses of 30-60 mcg/kg CJC-1295 1.
Detection and Anti-Doping Concerns
CJC-1295 can be detected in plasma at concentrations as low as 180 pg/mL using specialized LC-MS/MS methods after immunoaffinity capture 4.
These peptides are prohibited substances under World Anti-Doping Agency regulations.
Common Pitfalls
Do not assume these research doses translate to safe or effective clinical use—the studies were conducted in controlled research settings with careful monitoring and exclusion criteria.
Do not combine these peptides with other growth hormone secretagogues or exogenous GH without understanding the potential for excessive GH/IGF-I elevation and associated risks (glucose intolerance, edema, joint pain, potential neoplastic effects).
Do not use in patients with active malignancy or history of cancer—GH and IGF-I can promote tumor growth.
Avoid in patients with uncontrolled diabetes—GH is a counter-regulatory hormone that raises blood glucose.
Do not use during pregnancy or breastfeeding—no safety data exist for these populations.